RT Journal
A1 Bhatt DL
T1 ANtiplatelet therapy following myocardial infarction in patients with diabetes
JF JAMA
JO JAMA
YR 2012
FD September 5
VO 308
IS 9
SP 921
OP 922
DO 10.1001/2012.jama.11467
UL http://dx.doi.org/10.1001/2012.jama.11467
AB 
In this issue of JAMA, Andersson et al3 present a careful analysis of patients who have survived 30 days after discharge for a first-time MI in the Danish nationwide registry. The authors examine the benefit of the oral antiplatelet agent clopidogrel in 7247 patients with vs 51 604 without medication-treated diabetes. Consistent with other data, patients with diabetes had a significantly higher rate of mortality and reinfarction (25% vs 15%) over the follow-up period of up to 1 year. Notably, the apparent beneficial effect of clopidogrel vs no clopidogrel was lower in patients with than in those without diabetes: adjusted hazard ratios of 0.89 vs 0.75 for all-cause mortality, 0.93 vs 0.77 for cardiovascular mortality, and 1.00 vs 0.91 for the composite of death or reinfarction.